|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
|
Thyroid Neoplasm
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<i>In vivo</i>, BLU-667 potently inhibited growth of NSCLC and thyroid cancer xenografts driven by various <i>RET</i> mutations and fusions without inhibiting VEGFR2.
|
29657135 |
2018 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer is frequently associated with the oncogenic conversion of the RET receptor tyrosine kinase.
|
16778204 |
2006 |
|
Thyroid Neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Thyroid cancer is frequently associated to the activation of specific protein (RET, BRAF) and lipid [PI(3)K] kinases.
|
17891251 |
2007 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer (TC) is frequently associated with BRAF or RAS oncogenic mutations and RET/PTC rearrangements, with aberrant RAF-MEK-ERK and/or PI3K pathway activation.
|
26265449 |
2015 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
RET rearrangements have been proposed as identifying fingerprints for irradiation induced thyroid cancer in children.
|
11820615 |
2001 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
RET/PTC rearrangement in thyroid tumors.
|
12114746 |
2002 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hürthle cell carcinomas?
|
14668719 |
2003 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.
|
16634961 |
2006 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
RET/PTC is a characteristic genetic alteration frequently found in radiation-induced thyroid cancer in human populations.
|
22136268 |
2011 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
RET, a transmembrane receptor tyrosine kinase and a receptor for the glial cell-derived neurotrophic factor family ligands, was one of the first oncogenes to be identified, and has been shown to be an oncogene in thyroid cancer and pheochromocytoma.
|
22751117 |
2013 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, BRAF (B-RAF proto-oncogene, serine/threonine kinase) gene mutations, RAS (rat sarcoma) mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the known pathways playing a crucial role in the development of thyroid cancer.
|
25789503 |
2015 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
RET, BRAF and other protein kinases have been identified as major molecular players in thyroid cancer.
|
27058903 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer.
|
9794240 |
1998 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A G691S RET polymorphism was present with a higher frequency in radiation-induced epithelial thyroid tumours (55%) than in sporadic tumours (20%) and in control normal thyroid tissues (15%).
|
12085189 |
2002 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
A break-apart fluorescence in situ hybridization assay for detecting RET translocations in papillary thyroid carcinoma.
|
17954268 |
2007 |
|
Thyroid Neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
A deeper understanding of the molecular signaling of normal versus abnormal RET activity in cancer will enable the development of potential new treatments for patients with sporadic and inherited thyroid cancer or MEN 2 syndrome.
|
15982921 |
2005 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma.
|
12474140 |
2003 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma.
|
18631007 |
2008 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A prophylactic thyroidectomy was performed in three cases (5.4%) without clinical signs of thyroid tumor with diagnosed RET gene mutation.
|
24794415 |
2014 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Activating germline point mutations in the RET proto-oncogene are associated with multiple endocrine neoplasia types 2A, 2B, and familial medullary thyroid cancer (FMTC)-around 3% of thyroid cancer cases.
|
19465682 |
2009 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
All fusions identified were between RET and KIF5B genes, and no RET fusions to CCDC6 or NCOA4 genes, characteristic for thyroid cancer, were identified in the irradiated lung cells.
|
24346100 |
2014 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.
|
15273715 |
2004 |
|
Thyroid Neoplasm
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma.
|
12519890 |
2003 |